Key facts
- This page summarizes Sorrento Therapeutics, Inc.'s Form 4 filing for Celularity Inc (CELU).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Oct 2023, 17:16.
Sorrento Therapeutics, Inc. - 29 Sep 2023 Form 4 Insider Report for Celularity Inc (CELU)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- CELU
- Reported as of
- 29 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Oct 2023, 17:16:17 UTC
- Prior SEC filing
- 25 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Mohsin Y. Meghji Chief Restructuring Officer of Sorrento Therapeutics, Inc.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sorrento Therapeutics, Inc. filed Form 4 for Celularity Inc (CELU) on 05 Oct 2023.
Change
- Previous filing in this sequence was filed on 25 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CELU
transaction
Class A Common Stock
Sale
- Transaction value
- Shares
- -9,064,539
- Change %
- -44%
- Price
- Shares after
- 11,357,585
- Date
- 29 Sep 2023
- Ownership
- Direct
- Footnotes
- F1, F2
CELU
transaction
Class A Common Stock
Sale
- Transaction value
- Shares
- -6,307,158
- Change %
- -56%
- Price
- Shares after
- 5,050,427
- Date
- 05 Oct 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Sorrento Therapeutics, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
On September 29, 2023, the Reporting Person and Dr. Robert J. Hariri, M.D., Ph. D., ("Purchaser") entered into that certain Stock Purchase Agreement (the "SPA") pursuant to which the Purchaser agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of Class A common stock ("Celularity Common Shares") of Celularity Inc. ("Celularity") for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 Celularity Common Shares owned by the Reporting Person for an aggregate amount in cash equal to seventy percent of the 5-Day VWAP of the Celularity Common Shares calculated as of such subsequent closing date.
Footnote F2
Pursuant to the terms of the SPA, the Purchaser paid Sorrento $1.5 million on September 29, 2023. In connection with the transaction described in clause (ii) of footnote 1 above, the Purchaser paid Sorrento $1.0 million on October 5, 2023, as consideration for the transfer of 6,307,158 Celularity Common Shares; however, the transfer of the remaining 5,050,427 Celularity Common Shares in exchange for the $0.8 million of consideration remaining to be paid pursuant to the SPA has not yet been consummated as of the date hereof.